12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ACP-501: Phase I data

An open-label, U.S. Phase I trial in 16 patients with stable atherosclerosis showed that single ascending-doses of IV ACP-501...

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >